{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:34:06Z","timestamp":1792784046118,"version":"4.5.0"},"reference-count":51,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,1,1]],"date-time":"2017-01-01T00:00:00Z","timestamp":1483228800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,9,21]],"date-time":"2016-09-21T00:00:00Z","timestamp":1474416000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Ashfield Company"},{"DOI":"10.13039\/100009155","name":"Otsuka America Pharmaceutical, Inc.","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100009155","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","jad-journal.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Affective Disorders"],"published-print":{"date-parts":[[2017,1]]},"DOI":"10.1016\/j.jad.2016.09.006","type":"journal-article","created":{"date-parts":[[2016,9,20]],"date-time":"2016-09-20T00:18:58Z","timestamp":1474330738000},"page":"54-62","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Cost-effectiveness of brexpiprazole adjunctive treatment for major depressive disorder"],"prefix":"10.1016","volume":"207","author":[{"given":"Matthew","family":"Sussman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siddhesh A.","family":"Kamat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann","family":"Hartry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Legacy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruth","family":"Duffy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myrlene Sanon","family":"Aigbogun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jad.2016.09.006_bib1","first-page":"A34","article-title":"Guidelines for the treatment of patients with major depressive disorder","volume":"167","author":"American Psychiatric Association","year":"2010","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.jad.2016.09.006_bib2","unstructured":"AnalySource Drug Pricing Resource, 2015. \u3008https:\/\/www.analysource.com\u3009 (accessed 01.03.15.)."},{"key":"10.1016\/j.jad.2016.09.006_bib3","doi-asserted-by":"crossref","first-page":"540","DOI":"10.4088\/JCP.08m04629","article-title":"Extended-release quetiapine as adjunct to an antidepressant in patients with major depressive disorder: results of a randomized, placebo-controlled, double-blind study","volume":"70","author":"Bauer","year":"2009","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.jad.2016.09.006_bib4","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.jad.2009.04.017","article-title":"Economic evaluation of duloxetine versus serotonin selective reuptake inhibitors and venlafaxine XR in treating major depressive disorder in Scotland","volume":"120","author":"Benedict","year":"2010","journal-title":"J. Affect Disord."},{"key":"10.1016\/j.jad.2016.09.006_bib5","doi-asserted-by":"crossref","first-page":"507","DOI":"10.2165\/00019053-200927060-00006","article-title":"Determinants of direct cost differences among US employees with major depressive disorders using antidepressants","volume":"27","author":"Birnbaum","year":"2009","journal-title":"PharmacoEconomics"},{"key":"10.1016\/j.jad.2016.09.006_bib6","doi-asserted-by":"crossref","DOI":"10.1517\/14656566.2012.656590","article-title":"Treatment-emergent adverse events associated with atypical antipsychotics","volume":"13","author":"Cha","year":"2012","journal-title":"Expert Opin. Pharm."},{"key":"10.1016\/j.jad.2016.09.006_bib7","doi-asserted-by":"crossref","first-page":"39","DOI":"10.3810\/pgm.2010.07.2174","article-title":"Adjunctive aripiprazole, olanzapine, or quetiapine for major depressive disorder: an analysis of number needed to treat, number needed to harm, and likelihood to be helped or harmed","volume":"122","author":"Citrome","year":"2010","journal-title":"Postgrad. Med."},{"key":"10.1016\/j.jad.2016.09.006_bib8","doi-asserted-by":"crossref","first-page":"43","DOI":"10.2165\/11587620-000000000-00000","article-title":"If at first you don\u2019t succeed: a review of the evidence for antidepressant augmentation, combination and switching strategies","volume":"1","author":"Connolly","year":"2011","journal-title":"Drugs"},{"key":"10.1016\/j.jad.2016.09.006_bib9","doi-asserted-by":"crossref","first-page":"397","DOI":"10.4088\/JCP.v64n0406","article-title":"Remission, residual symptoms, and nonresponse in the usual treatment of major depression in managed clinical practice","volume":"64","author":"Cuffel","year":"2003","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.jad.2016.09.006_bib10","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta17540","article-title":"Lithium or an atypical antipsychotic drug in the management of treatment-resistant depression: a systematic review and economic evaluation","volume":"17","author":"Edwards","year":"2013","journal-title":"Health Technol. Assess."},{"key":"10.1016\/j.jad.2016.09.006_bib11","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1017\/S1461145710000015","article-title":"Extended-release quetiapine fumarate (quetiapine XR) as adjunctive therapy in major depressive disorder (MDD) in patients with an inadequate response to ongoing antidepressant treatment: a multicenter, randomized, double-blind, placebo-controlled study","volume":"13","author":"El-Khalili","year":"2010","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.jad.2016.09.006_bib12","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1176\/ajp.2006.163.7.1161","article-title":"A comparison of mirtazapine and nortriptyline following two consecutive failed medication treatments for depressed outpatients: a START*D report","volume":"163","author":"Fava","year":"2006","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.jad.2016.09.006_bib13","doi-asserted-by":"crossref","first-page":"e1001547","DOI":"10.1371\/journal.pmed.1001547","article-title":"Burden of depressive disorders by country, sex, age, and year: findings from the Global Burden of Disease study 2010","volume":"10","author":"Ferrari","year":"2013","journal-title":"PLoS Med."},{"issue":"8","key":"10.1016\/j.jad.2016.09.006_bib14","first-page":"1063","article-title":"Number needed to treat to harm for discontinuation due to adverse events in the treatment of bipolar depression, major depressive disorder, and generalized anxiety disorder with atypical antipsychotics","volume":"72","author":"Gao","year":"2011","journal-title":"J. Clin. Psychol."},{"key":"10.1016\/j.jad.2016.09.006_bib15","first-page":"S1","article-title":"Major depressive disorder in the primary care setting: Strategies to achieve remission and recovery","volume":"64","author":"Gaynes","year":"2015","journal-title":"J. Fam. Pract."},{"key":"10.1016\/j.jad.2016.09.006_bib16","unstructured":"Gelenberg AJ, Freeman MP, Markowitz JC, et al., 2010. American Psychiatric Association: practice guideline for the treatment of patients with major depressive disorder, third ed. Arlington, Virginia."},{"key":"10.1016\/j.jad.2016.09.006_bib17","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/1471-2296-8-28","article-title":"Observational studies of depression in primary care: what do we know?","volume":"8","author":"Gilchrist","year":"2007","journal-title":"BMC Fam. Pract."},{"key":"10.1016\/j.jad.2016.09.006_bib18","doi-asserted-by":"crossref","first-page":"155","DOI":"10.4088\/JCP.14m09298","article-title":"The economic burden of adults with major depressive disorder in the United States (2005 and 2010)","volume":"76","author":"Greenberg","year":"2015","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.jad.2016.09.006_bib19","doi-asserted-by":"crossref","first-page":"S53","DOI":"10.1007\/s40263-012-0034-x","article-title":"Management of chronic depressive patients with residual symptoms","volume":"27","author":"Han","year":"2013","journal-title":"CNS Drugs"},{"key":"10.1016\/j.jad.2016.09.006_bib20","unstructured":"IHS Global Pricing and Reimbursement. \u3008https:\/\/www.ihs.com\/products\/pricing-and-reimbursement-market-analysis.html\u3009. (accessed 17.03.15.)."},{"key":"10.1016\/j.jad.2016.09.006_bib21","doi-asserted-by":"crossref","first-page":"2475","DOI":"10.1185\/03007995.2010.517716","article-title":"Direct and indirect costs of employees with treatment-resistant and non-treatment-resistant major depressive disorder","volume":"26","author":"Ivanova","year":"2010","journal-title":"Curr. Med. Res. Opin."},{"key":"10.1016\/j.jad.2016.09.006_bib22","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.psc.2011.11.005","article-title":"The costs of depression","volume":"35","author":"Kessler","year":"2012","journal-title":"Psychiatr. Clin. North Am."},{"key":"10.1016\/j.jad.2016.09.006_bib23","doi-asserted-by":"crossref","first-page":"3095","DOI":"10.1001\/jama.289.23.3095","article-title":"The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R)","volume":"289","author":"Kessler","year":"2003","journal-title":"JAMA"},{"key":"10.1016\/j.jad.2016.09.006_bib24","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1001\/archpsyc.62.6.593","article-title":"Lifetime prevalence and age-of-onset distributions of DSM-IV Disorders in the National Comorbidity Survey Replication","volume":"62","author":"Kessler","year":"2005","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.jad.2016.09.006_bib25","first-page":"e188","article-title":"Effect of inadequate response to treatment in patients with depression","volume":"16","author":"Knoth","year":"2010","journal-title":"Am. J. Manag. Care"},{"key":"10.1016\/j.jad.2016.09.006_bib26","unstructured":"Legacy, S., McMorrow, D., Duffy, R.A., et al., 2015. Delay in use of adjunct atypical antipsychotic treatment for major depressive disorder is associated with higher physician office visits and costs. In: Proceedings of the Abstract presented at the American Psychiatric Association 168th Annual Meeting; May 16\u201320, 2015; Toronto, Canada."},{"key":"10.1016\/j.jad.2016.09.006_bib27","doi-asserted-by":"crossref","first-page":"173","DOI":"10.2165\/00044011-200929030-00004","article-title":"Cost effectiveness of venlafaxine compared with generic fluoxetine or generic amitriptyline in major depressive disorder in the UK","volume":"29","author":"Lenox-Smith","year":"2009","journal-title":"Clin. Drug Investig."},{"key":"10.1016\/j.jad.2016.09.006_bib28","first-page":"S8","article-title":"A budget-impact and cost-effectiveness model for second-line treatment of major depression","volume":"13","author":"Malone","year":"2007","journal-title":"J. Manag. Care"},{"key":"10.1016\/j.jad.2016.09.006_bib29","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1002\/da.20505","article-title":"Nonresponse, partial response, and failure to achieve remission: humanistic and cost burden in major depressive disorder","volume":"26","author":"Mauskopf","year":"2009","journal-title":"Depress. Anxiety"},{"key":"10.1016\/j.jad.2016.09.006_bib30","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1176\/appi.ajp.2009.09030312","article-title":"Atypical antipsychotic augmentation in major depressive disorder: a metaanalysis of placebo-controlled randomized trials","volume":"166","author":"Nelson","year":"2009","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.jad.2016.09.006_bib31","first-page":"S5","article-title":"Definitions of antidepressant treatment response, remission, nonresponse, partial response, and other relevant outcomes: a focus on treatment-resistant depression","volume":"62","author":"Nierenberg","year":"2001","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.jad.2016.09.006_bib32","first-page":"S13","article-title":"Prevention of relapse and recurrence in depression: the role of longterm pharmacotherapy and psychotherapy","volume":"64","author":"Nierenberg","year":"2003","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.jad.2016.09.006_bib33","doi-asserted-by":"crossref","first-page":"516","DOI":"10.3111\/13696998.2010.506371","article-title":"Cost effectiveness of escitalopram versus SNRIs in second-step treatment of major depressive disorder in Sweden","volume":"13","author":"Nordstrom","year":"2010","journal-title":"J. Med. Econ."},{"key":"10.1016\/j.jad.2016.09.006_bib34","unstructured":"Otsuka Pharmaceutical Co., Ltd. Rexulti (brexpiprazole), 2015. \u3008https:\/\/www.rexulti.com\/us\/mdd\/important-safety-information\/?ceid=9086&utm_source=google&utm_medium=cpc&utm_campaign=brandedmdd&utm_term=brexpiprazole&utm_content=textad\u3009. (accessed 28.12.15.)."},{"key":"10.1016\/j.jad.2016.09.006_bib35","doi-asserted-by":"crossref","first-page":"S16","DOI":"10.4088\/JCP.8133su1c.03","article-title":"Managing partial response or nonresponse: switching, augmentation, and combination strategies for major depressive disorder","volume":"70","author":"Papakostas","year":"2009","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.jad.2016.09.006_bib36","doi-asserted-by":"crossref","first-page":"S29","DOI":"10.1007\/s40263-012-0031-0","article-title":"Atypical antipsychotic augmentation strategies in the context of guideline-based care for the treatment of major depressive disorder","volume":"27","author":"Patkar","year":"2013","journal-title":"CNS Drugs"},{"key":"10.1016\/j.jad.2016.09.006_bib37","unstructured":"Red Book. \u3008http:\/\/sites.truvenhealth.com\/redbook\/index.html\u3009 (accessed 01.03.15.)."},{"key":"10.1016\/j.jad.2016.09.006_bib38","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1176\/ajp.2006.163.11.1905","article-title":"Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report","volume":"163","author":"Rush","year":"2006","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.jad.2016.09.006_bib39","doi-asserted-by":"crossref","first-page":"341","DOI":"10.4088\/JCP.v65n0309","article-title":"The cost consequences of treatment-resistant depression","volume":"65","author":"Russell","year":"2004","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.jad.2016.09.006_bib40","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.vhri.2013.06.004","article-title":"Cost-effectiveness analysis of aripiprazole augmentation treatment of patients with major depressive disorder compared to olanzapine and quetiapine augmentation in Turkey: a microsimulation approach","volume":"2","author":"Saylan","year":"2013","journal-title":"Value Health Reg. Issues"},{"key":"10.1016\/j.jad.2016.09.006_bib41","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1176\/appi.ajp.158.1.131","article-title":"A novel augmentation strategy for treating resistant major depression","volume":"158","author":"Shelton","year":"2001","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.jad.2016.09.006_bib42","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.4088\/JCP.v66n1012","article-title":"Olanzapine\/fluoxetine combination for treatment-resistant depression: a controlled studyof SSRI and nortriptyline resistance","volume":"66","author":"Shelton","year":"2005","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.jad.2016.09.006_bib43","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.4088\/JCP.v67n0808","article-title":"Recovery from depression helps predict lower health services costs","volume":"67","author":"Simon","year":"2006","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.jad.2016.09.006_bib44","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1007\/s10198-006-0008-3","article-title":"Resource use and costs associated with patients treated for depression in primary care","volume":"8","author":"Sobocki","year":"2007","journal-title":"Eur. J. Health Econ."},{"key":"10.1016\/j.jad.2016.09.006_bib45","doi-asserted-by":"crossref","first-page":"e1001403","DOI":"10.1371\/journal.pmed.1001403","article-title":"Adjunctive atypical antipsychotic treatment for major depressive disorder: a meta-analysis of depression, quality of life, and safety outcomes","volume":"10","author":"Spielmans","year":"2013","journal-title":"PLoS Med."},{"key":"10.1016\/j.jad.2016.09.006_bib46","first-page":"642","article-title":"Cost-effectiveness of adjunctive therapy with atypical antipsychotics for acute treatment of major depressive disorder","volume":"46","author":"Taneja","year":"2012","journal-title":"Ann. Pharm."},{"key":"10.1016\/j.jad.2016.09.006_bib47","doi-asserted-by":"crossref","first-page":"224","DOI":"10.4088\/JCP.v68n0207","article-title":"Olanzapine\/fluoxetine combination, olanzapine, and fluoxetine in treatment-resistant major depressive disorder","volume":"68","author":"Thase","year":"2007","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.jad.2016.09.006_bib48","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.4088\/JCP.14m09688","article-title":"Efficacy and safety of adjunctive brexpiprazole 2mg in major depressive disorder: a phase 3, randomized, placebo-controlled study in patients with inadequate response to antidepressants","volume":"76","author":"Thase","year":"2015","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.jad.2016.09.006_bib49","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.4088\/JCP.14m09689","article-title":"Adjunctive brexpiprazole 1 and 3mg for patients with major depressive disorder following inadequate response to antidepressants: a phase 3, randomized, double-blind study","volume":"76","author":"Thase","year":"2015","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.jad.2016.09.006_bib50","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1097\/01.jcp.0000138769.61600.e4","article-title":"Cost and effectiveness of venlafaxine extended-release and selective serotonin reuptake inhibitors in the acute phase of outpatient treatment for major depressive disorder","volume":"24","author":"Trivedi","year":"2004","journal-title":"J. Clin. Psychopharm."},{"key":"10.1016\/j.jad.2016.09.006_bib51","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1478-7547-10-1","article-title":"Methodologies used in cost-effectiveness models for evaluating treatments in major depressive disorder: a systematic review","volume":"10","author":"Zimovetz","year":"2012","journal-title":"Cost. Eff. Resour. Alloc."}],"container-title":["Journal of Affective Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165032716310321?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165032716310321?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,8]],"date-time":"2018-09-08T04:55:44Z","timestamp":1536382544000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165032716310321"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,1]]},"references-count":51,"alternative-id":["S0165032716310321"],"URL":"https:\/\/doi.org\/10.1016\/j.jad.2016.09.006","relation":{},"ISSN":["0165-0327"],"issn-type":[{"value":"0165-0327","type":"print"}],"subject":[],"published":{"date-parts":[[2017,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cost-effectiveness of brexpiprazole adjunctive treatment for major depressive disorder","name":"articletitle","label":"Article Title"},{"value":"Journal of Affective Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jad.2016.09.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}